According to TipRanks.com, Baker is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.0% and a 42.6% success rate. Baker covers the Industrial Goods sector, focusing on stocks such as Southwest Airlines, JetBlue Airways, and Spirit Airlines.
Currently, the analyst consensus on Alaska Air is a Strong Buy with an average price target of $68.43, implying a 57.3% upside from current levels. In a report issued on July 8, Morgan Stanley also maintained a Buy rating on the stock with a $73.00 price target.
Based on Alaska Air’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.68 billion and GAAP net loss of $143 million. In comparison, last year the company earned revenue of $797 million and had a GAAP net loss of $131 million.
Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alaska Air Group, Inc. is a holding company, which through its subsidiaries, Alaska Airlines, Inc. and Horizon Air Industries, Inc., engages in the provision of air transportation services. It operates through three segments: Alaska Mainline, Alaska Regional and Horizon. The Alaska Mainline segment includes flying Boeing 737 jets and all associated revenues and costs. The Alaska Regional segment records actual on-board passenger revenue, less costs such as fuel, distribution costs, and payments made to Horizon, SkyWest and PenAir under the respective Capacity Purchase Agreements. The Horizon segment operates turboprop Q400 aircraft. The company was founded in 1985 and is headquartered in Seattle, WA.
Read More on ALK:
- J.P. Morgan Thinks Uniper SE’s Stock is Going to Recover
- William Blair Remains a Hold on SPS Commerce (SPSC)
- Deutsche Bank AG (DB) Gets a Buy Rating from Goldman Sachs
- Guggenheim Maintains a Buy Rating on Amazon (AMZN)
- Analysts Conflicted on These Healthcare Names: Avadel Pharmaceuticals (AVDL), I-MAB (IMAB) and Generation Bio (GBIO)